ECSP11011459A - Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas - Google Patents
Composiciones sublinguales de dexmedetomidina y métodos de uso de ellasInfo
- Publication number
- ECSP11011459A ECSP11011459A EC2011011459A ECSP11011459A ECSP11011459A EC SP11011459 A ECSP11011459 A EC SP11011459A EC 2011011459 A EC2011011459 A EC 2011011459A EC SP11011459 A ECSP11011459 A EC SP11011459A EC SP11011459 A ECSP11011459 A EC SP11011459A
- Authority
- EC
- Ecuador
- Prior art keywords
- dexmedetomidine
- methods
- sublingual compositions
- sublingual
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/06—Head
- A61M2210/0625—Mouth
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proveen formulaciones sublinguales analgésicas de dexmedetomidina y métodos de uso de ellas para su uso en la prevención, el tratamiento y la administración del dolor y otras condiciones.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17873009P | 2009-05-15 | 2009-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011459A true ECSP11011459A (es) | 2012-01-31 |
Family
ID=43085620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011459A ECSP11011459A (es) | 2009-05-15 | 2011-11-14 | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas |
Country Status (21)
Country | Link |
---|---|
US (1) | US20110021588A1 (es) |
EP (2) | EP3305281A1 (es) |
JP (2) | JP6172938B2 (es) |
KR (1) | KR101859486B1 (es) |
CN (2) | CN106511273A (es) |
AU (1) | AU2010248776B2 (es) |
BR (1) | BRPI1010567A2 (es) |
CA (1) | CA2762107A1 (es) |
CL (1) | CL2011002858A1 (es) |
CO (1) | CO6460767A2 (es) |
CR (1) | CR20110596A (es) |
DO (1) | DOP2011000354A (es) |
EC (1) | ECSP11011459A (es) |
HN (1) | HN2011003011A (es) |
IL (1) | IL216159A (es) |
MX (1) | MX2011011950A (es) |
NZ (1) | NZ596976A (es) |
PE (1) | PE20120713A1 (es) |
RU (1) | RU2572692C2 (es) |
SG (1) | SG175979A1 (es) |
WO (1) | WO2010132882A2 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130096170A1 (en) | 2011-10-14 | 2013-04-18 | Hospira, Inc. | Methods of treating pediatric patients using dexmedetomidine |
EP2787970B1 (en) | 2011-12-11 | 2018-04-11 | Recro Pharma, Inc. | Intranasal dexmedetomidine compositions and methods of use thereof |
US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
CA2865593A1 (en) * | 2012-02-27 | 2013-09-06 | Eye Therapies Llc | Compositions and methods for the treatment of migraine |
ES2659271T3 (es) | 2012-10-15 | 2018-03-14 | Orion Corporation | Método veterinario para aliviar la aversión al ruido |
EP2792352A1 (en) * | 2013-04-16 | 2014-10-22 | Laboratorios Del. Dr. Esteve, S.A. | Alpha-2 adrenoreceptor and sigma receptor ligand combinations |
US20150273215A1 (en) * | 2014-03-26 | 2015-10-01 | Pacesetter, Inc. | Systems and methods for assessment of pain and other parameters during trial neurostimulation |
EP3054930B1 (en) * | 2013-10-07 | 2020-12-02 | Teikoku Pharma USA, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
WO2015054059A2 (en) | 2013-10-07 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
CN105764494A (zh) | 2013-10-07 | 2016-07-13 | 帝国制药美国公司 | 右旋美托咪啶经皮递送装置及其使用方法 |
RU2557882C1 (ru) * | 2014-07-08 | 2015-07-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) | Способ проведения премедикации при плановом хирургическом лечении |
MA41689A (fr) * | 2014-10-15 | 2017-08-22 | Bioxcel Corp | Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine |
JP7065871B2 (ja) * | 2016-12-13 | 2022-05-12 | オリオン コーポレーション | イヌの分離不安症の治療における使用のためのデクスメデトミジンまたはメデトミジン |
KR20240031326A (ko) * | 2016-12-31 | 2024-03-07 | 바이오엑셀 테라퓨틱스 인코포레이티드 | 불안의 치료를 위한 설하 덱스메데토미딘의 용도 |
MX2020014000A (es) | 2018-06-27 | 2021-06-15 | Bioxcel Therapeutics Inc | Formulaciones en lámina que contienen dexmedetomidina y métodos para producirlas. |
CN112138250B (zh) * | 2019-06-28 | 2023-04-14 | 四川普锐特药业有限公司 | 保持给药均一度的药物流体分配器及右美托咪定鼻喷器 |
MX2022000709A (es) | 2019-07-19 | 2022-05-19 | Bioxcel Therapeutics Inc | Regimenes de tratamiento con dexmedetomidina no sedante. |
CN113827590A (zh) * | 2020-06-08 | 2021-12-24 | 四川普锐特药业有限公司 | 右美托咪定在助眠药物制备中的应用 |
US20220031664A1 (en) * | 2020-07-28 | 2022-02-03 | Melt Pharmaceuticals, Inc. | Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications |
WO2024055042A1 (en) * | 2022-09-11 | 2024-03-14 | Bioxcel Therapeutics, Inc. | Methods for treating agitation in community settings |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
CN118542852B (zh) * | 2024-07-30 | 2024-10-01 | 山东则正医药技术有限公司 | 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2206880B (en) * | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
US5124157A (en) * | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
US5217718A (en) * | 1989-08-18 | 1993-06-08 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
FI894911A0 (fi) * | 1989-10-17 | 1989-10-17 | Farmos Oy | En terapeutiskt vaerdefull foerening. |
SG47527A1 (en) * | 1990-12-05 | 1998-04-17 | Gen Hospital Corp | Devices for treating pulmonary vasoconstriction and asthma |
GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
US5571840A (en) * | 1993-06-22 | 1996-11-05 | The Regents Of The University Of Michigan | Method for treating central nervous system ischemia |
US5713907A (en) * | 1995-07-20 | 1998-02-03 | Endotex Interventional Systems, Inc. | Apparatus and method for dilating a lumen and for inserting an intraluminal graft |
GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
US20030077227A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
US20050281752A1 (en) | 1997-10-01 | 2005-12-22 | Dugger Harry A Iii | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system |
AR015744A1 (es) * | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
US6716867B1 (en) * | 1998-04-01 | 2004-04-06 | Orion Corporation | Use of dexmedetomidine for ICU sedation |
US7001609B1 (en) * | 1998-10-02 | 2006-02-21 | Regents Of The University Of Minnesota | Mucosal originated drug delivery systems and animal applications |
PT1117390E (pt) * | 1998-10-02 | 2005-01-31 | 3M Innovative Properties Co | Sistemas de distribuicao de farmacos originarios da mucosa e aplicacoes em animais |
GB9913677D0 (en) * | 1999-06-11 | 1999-08-11 | Imperial College | Formulation |
AUPR184500A0 (en) * | 2000-12-01 | 2001-01-04 | Drug Delivery Solutions Pty Ltd | Dispensing device |
WO2002089794A1 (en) * | 2001-05-07 | 2002-11-14 | Universite Catholique De Louvain | Method for treating neuropathic pain and pharmaceutical preparation therefor |
WO2002094238A1 (en) * | 2001-05-24 | 2002-11-28 | Alexza Molecular Delivery Corporation | Delivery of anti-migraine compounds through an inhalation route |
FR2834212B1 (fr) * | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
IL147921A0 (en) * | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
US20090117054A1 (en) * | 2005-03-29 | 2009-05-07 | University Of Kentucky Research Foundation | Sublingual spray for the treatment of pain |
RU2432950C2 (ru) * | 2006-01-25 | 2011-11-10 | Инсис Терапьютикс Инк. | Подъязычный спрей на основе фентанила |
DK1986642T3 (da) * | 2006-02-13 | 2014-02-03 | Orient Pharma Samoa Co Ltd | Kombination af alfa-2-receptoragonist (clonidin) og et antimuscarinmiddel (oxybutynin) til behandling af sialorrhoea |
US20080021074A1 (en) * | 2006-06-29 | 2008-01-24 | Questcor Pharmaceuticals, Inc. | Pharmaceutical Compositions and Related Methods of Treatment |
CN101057830A (zh) * | 2007-05-10 | 2007-10-24 | 北京天川军威医药技术开发有限公司 | 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法 |
-
2010
- 2010-05-17 CA CA2762107A patent/CA2762107A1/en not_active Abandoned
- 2010-05-17 PE PE2011001958A patent/PE20120713A1/es not_active Application Discontinuation
- 2010-05-17 US US12/781,628 patent/US20110021588A1/en not_active Abandoned
- 2010-05-17 KR KR1020117027466A patent/KR101859486B1/ko active IP Right Grant
- 2010-05-17 CN CN201610753813.7A patent/CN106511273A/zh active Pending
- 2010-05-17 NZ NZ596976A patent/NZ596976A/en not_active IP Right Cessation
- 2010-05-17 SG SG2011082666A patent/SG175979A1/en unknown
- 2010-05-17 WO PCT/US2010/035136 patent/WO2010132882A2/en active Application Filing
- 2010-05-17 BR BRPI1010567A patent/BRPI1010567A2/pt not_active IP Right Cessation
- 2010-05-17 RU RU2011151059/15A patent/RU2572692C2/ru active
- 2010-05-17 EP EP17187813.5A patent/EP3305281A1/en not_active Withdrawn
- 2010-05-17 AU AU2010248776A patent/AU2010248776B2/en not_active Ceased
- 2010-05-17 MX MX2011011950A patent/MX2011011950A/es active IP Right Grant
- 2010-05-17 CN CN2010800211820A patent/CN102639131A/zh active Pending
- 2010-05-17 EP EP10775671.0A patent/EP2429521B1/en active Active
- 2010-05-17 JP JP2012511068A patent/JP6172938B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-06 IL IL216159A patent/IL216159A/en active IP Right Grant
- 2011-11-14 DO DO2011000354A patent/DOP2011000354A/es unknown
- 2011-11-14 CL CL2011002858A patent/CL2011002858A1/es unknown
- 2011-11-14 HN HN2011003011A patent/HN2011003011A/es unknown
- 2011-11-14 CR CR20110596A patent/CR20110596A/es unknown
- 2011-11-14 EC EC2011011459A patent/ECSP11011459A/es unknown
- 2011-11-15 CO CO11155150A patent/CO6460767A2/es active IP Right Grant
-
2015
- 2015-09-11 JP JP2015179975A patent/JP2016029055A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2010248776A1 (en) | 2012-01-12 |
WO2010132882A2 (en) | 2010-11-18 |
IL216159A (en) | 2015-10-29 |
JP2012526854A (ja) | 2012-11-01 |
EP2429521B1 (en) | 2017-10-18 |
BRPI1010567A2 (pt) | 2016-03-15 |
CA2762107A1 (en) | 2010-11-18 |
WO2010132882A3 (en) | 2011-03-31 |
KR20120008058A (ko) | 2012-01-25 |
CN102639131A (zh) | 2012-08-15 |
CL2011002858A1 (es) | 2012-06-22 |
NZ596976A (en) | 2014-05-30 |
JP6172938B2 (ja) | 2017-08-02 |
WO2010132882A8 (en) | 2011-12-29 |
AU2010248776B2 (en) | 2013-06-06 |
RU2572692C2 (ru) | 2016-01-20 |
CN106511273A (zh) | 2017-03-22 |
SG175979A1 (en) | 2011-12-29 |
EP2429521A2 (en) | 2012-03-21 |
HN2011003011A (es) | 2014-12-01 |
EP2429521A4 (en) | 2013-08-21 |
CR20110596A (es) | 2012-03-26 |
CO6460767A2 (es) | 2012-06-15 |
DOP2011000354A (es) | 2012-07-15 |
US20110021588A1 (en) | 2011-01-27 |
IL216159A0 (en) | 2012-01-31 |
JP2016029055A (ja) | 2016-03-03 |
PE20120713A1 (es) | 2012-07-08 |
RU2011151059A (ru) | 2013-06-20 |
EP3305281A1 (en) | 2018-04-11 |
KR101859486B1 (ko) | 2018-06-28 |
MX2011011950A (es) | 2012-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011459A (es) | Composiciones sublinguales de dexmedetomidina y métodos de uso de ellas | |
CL2008001114A1 (es) | Compuestos derivados de bencimidazol; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como vejiga sobreactiva, dolor, obesidad, convulsiones, entre otras. | |
CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
UY32728A (es) | Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia | |
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2013000016A1 (es) | Compuestos derivados de imidazopiridina; procedimiento de preparacion; composicion farmaceutica y su uso en el tratamiento del cancer. | |
CL2008001373A1 (es) | Compuestos derivados de fenilamino-benceno sustituidos; metodo de preparacion; composicion farmaceutica; kit farmceuticos; y uso de dichos compuestos en el tratamiento del cancer. | |
NI201000044A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
CL2011000214A1 (es) | Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona. | |
CL2011003160A1 (es) | Compuestos derivados de heterociclicos, moduladores cb2; composicion farmaceutica que los comprende; y uso en el tratamiento de enfermedades reumaticas, autoinmune, inflamatorias, dolor, entre otras. | |
MX2012007933A (es) | Composiciones de dexmedetomidina transdermicas topicas y metodos para su uso. | |
NI201000015A (es) | Bromhidrato de bupropión y aplicaciones terapéuticas | |
CL2008002545A1 (es) | Compuestos derivados de fenoxi-bencil-carbamoilo; composicion farmaceutica; procedimiento para preparar la composicion farmaceutica; y su uso en el tratamiento del dolor. | |
CL2012001757A1 (es) | Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica; y su uso en el tratamiento de infecciones micoticas. | |
CL2011000168A1 (es) | Compuestos derivados de narciclasina y pancratistatina; procedimiento de preparación; composición farmacéutica; combinación farmacéutica; y su uso para el tratamiento del cáncer. | |
CL2008002060A1 (es) | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. | |
EP2611799A4 (en) | PHARMACEUTICAL COMPOSITIONS OF LINEZOLID | |
ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
CO6480929A2 (es) | Procedimiento de uso del factor liberador de corticotropina para el tratamiento del cancer | |
EA201270547A1 (ru) | Фармацевтическая композиция | |
CR20120617A (es) | Combinación de inhibidores de xantna oxidasa y antagonistas del receptor de angiotensina ii y su uso | |
CO6640306A2 (es) | Combinación de inhibidores de xantina oxidasa y antagonistas del receptor de angiotensina ii y su uso | |
TR201100152A2 (tr) | Amlodipin içeren efervesan bileşimler. |